App-Quantinova.ai

Studying Methylation Status of Protein Tyrosine Phosphatase Receptor Gamma (PTPRG) in Chronic Myeloid Leukemia Patients in the State of Qatar

Mohamed Ismail - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

L-Tyrosine

Excellent Response to Blinatumomab in Children and Young Adults with Refractory B Lineage Acute Lymphoblastic Leukaemia for Persistent MRD or after Debulking Chemotherapy for Higher Disease Burden

Vasudha Rao - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Down syndrome

Blinatumomab

Osteoclast Stimulatory Transmembrane Protein (OCSTAMP) mRNA Levels and Clinical Variables in Persons with Plasma Cell Myeloma

Ya-Lan Zhou - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

Detecting Complex Mutations in Myeloid Leukemia Using the GeneReader NGS System and QIAact Myeloid DNA UMI Panel

Veronique Laloux - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB

Anna L. Brown - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Idelalisib in Patients with B-Cell Lymphoma

Franck Morschhauser - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Waldenstrom’s macroglobulinemia

Tirabrutinib

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma

Gilles Salles - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Waldenstrom’s macroglobulinemia

Entospletinib

Retrospective Cohort Study Assessing the Prognostic Value of Baseline Necrosis on PET-CT in Hodgkin Lymphoma

Nuno Borges - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

N/A

Single Center Retrospective Study of Essential Thrombocythaemia Diagnosed Patients Treated with Interferon - Benefit and Tolerability

Joana Desterro - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Essential thrombocythemia

Interferon

CD47 but Not Calreticulin Is over Expressed in Patients with Myeloproliferative Neoplasms

Kristian Boasman - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myeloid neoplasms

Hydroxyurea

Azacitidine Improves Outcome in Patients with MDS and AML with High Risk Cytogenetics - a Single Center Experience

Vidhya Murthy - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Vidaza

Acitretin Reduces L-Selectin Expression and Tumour Cell Homing in Chronic Lymphocytic Leukaemia (CLL)

Saad Ahmed - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

DMSO

Efficacy and Safety of Ibrutinib (IBR) after Venetoclax (VEN) Treatment in IBR-Naïve Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Follow-up of Patients from the MURANO Study

Richard Greil - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Cyclophosphamide

Single-Agent Ibrutinib Versus Chlorambucil-Obinutuzumab As First-Line Treatment in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL): Results of a Cross-Trial Comparison

Alessandra Tedeschi - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Obinutuzumab

Encouraging Outcomes for Patients with Multiple Myeloma Treated in Early Phase Clinical Trials: A Single Centre and Meta-Analysis

Anna Cowley - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

N/A

34-Year Single Center Observational Review of Ex-Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplants for Chronic Myeloid Leukemia

Philippa Woolley - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Myelogenous Leukemia

N/A

Flow Cytometry Assay to Monitor Effectiveness of Gene Therapy Correction in Peripheral Blood Mononuclear Cells of Gaucher Disease Type I Patients

Cecilia Barese - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Gaucher disease 1

beta-glucocerebrosidase

Assessment of Sickle Cell Disease Pain Management in the Whittington Hospital Emergency Department

Leena Al Shaman - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

N/A

Impact of Post-Hematopoietic Cell Transplant (HCT) Survival on Cost-Effectiveness of CPX-351 Versus 7+3 in the Treatment of Therapy-Related AML or AML-MRC in the United States

Anuraag Kansal - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

daunorubicin + cytarabine

Matching Adjusted Indirect Comparison to Assess the Relative Efficacy of Idelalisib in Double-Refractory Follicular Lymphoma

Nishanthan Rajakumaraswamy - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non-Hodgkin's Lymphoma

Idelalisib

Filters

45280 Abstracts